Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer

被引：34

作者：

Torrisi, R

Baglietto, L

Johansson, H

Veronesi, G

Bonanni, B

Guerrieri-Gonzaga, A

Ballardini, B

Decensi, A

机构：

[1] European Inst Oncol, Div Chemoprevent, I-20141 Milan, Italy

[2] European Inst Oncol, Lab Med Unit, I-20141 Milan, Italy

[3] European Inst Oncol, Div Epidemiol & Biostat, I-20141 Milan, Italy

[4] European Inst Oncol, Div Senol, I-20141 Milan, Italy

来源：

BRITISH JOURNAL OF CANCER | 2001年 / 85卷 / 12期

关键词：

breast cancer prevention; SERMs; IGF system;

D O I：

10.1054/bjoc.2001.2191

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The effect on the IGF system of 60 mg and 600 mg daily of raloxifene administered for 2 weeks prior to surgery was investigated in 37 postmenopausal women with breast cancer. Raloxifene significantly decreased insulin-like growth factor (IGF-I) as compared to placebo (P < 0.05) with no dose-response relationship. No significant change was observed in IGFBP-3, while the IGF-I/IGFBP-3 molar ratio was decreased by treatment, with a statistically significant effect only for the higher dose. Given that high plasma levels of IGF-I have been suggested as a risk factor for breast cancer, these findings provide further support for the potential activity of raloxifene in breast cancer prevention. (C) 2001 Cancer Research Campaign.

引用

页码：1838 / 1841

页数：4

共 33 条

[1]

BASERGA R, 1995, CANCER RES, V55, P249

[2] Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis [J].

Boonen, S ;

Mohan, S ;

Dequeker, J ;

Aerssens, J ;

Vanderschueren, D ;

Verbeke, G ;

Broos, P ;

Bouillon, R ;

Baylink, DJ .

JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (12) :2150-2158

[3] Chemoprevention of breast cancer [J].

Brown, PH ;

Lippman, SM .

BREAST CANCER RESEARCH AND TREATMENT, 2000, 62 (01) :1-17

[4] Insulin-like growth factor-I: a key regulator of human cancer risk? [J].

Burroughs, KD ;

Dunn, SE ;

Barrett, JC ;

Taylor, JA .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (07) :579-581

[5] PHASE-II EVALUATION OF LY156758 IN METASTATIC BREAST-CANCER [J].

BUZDAR, AU ;

MARCUS, C ;

HOLMES, F ;

HUG, V ;

HORTOBAGYI, G .

ONCOLOGY, 1988, 45 (05) :344-345

[6] Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial [J].

Cauley, JA ;

Norton, L ;

Lippman, ME ;

Eckert, S ;

Krueger, KA ;

Purdie, DW ;

Farrerons, J ;

Karasik, A ;

Mellstrom, D ;

Ng, KW ;

Stepan, JJ ;

Powles, TJ ;

Morrow, M ;

Costa, A ;

Silfen, SL ;

Walls, EL ;

Schmitt, H ;

Muchmore, DB ;

Jordan, VC .

BREAST CANCER RESEARCH AND TREATMENT, 2001, 65 (02) :125-134

[7] Insulin-like growth factor-I and bone mineral density [J].

Collins, D ;

Woods, A ;

Herd, R ;

Blake, G ;

Fogelman, I ;

Wheeler, M ;

Swaminathan, R .

BONE, 1998, 23 (01) :13-16

[8]

CUMMINGS S, 2000, NIH WORKSH SERMS NAT, P126

[9] The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE randomized trial [J].

Cummings, SR ;

Eckert, S ;

Krueger, KA ;

Grady, D ;

Powles, TJ ;

Cauley, JA ;

Norton, L ;

Nickelsen, T ;

Bjarnason, NH ;

Morrow, M ;

Lippman, ME ;

Black, D ;

Glusman, JE ;

Costa, A ;

Jordan, VC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (23) :2189-2197

[10] INHIBITION OF ACCESS OF BOUND SOMATOMEDIN TO MEMBRANE-RECEPTOR AND IMMUNOBINDING SITES - A COMPARISON OF RADIORECEPTOR AND RADIOIMMUNOASSAY OF SOMATOMEDIN IN NATIVE AND ACID-ETHANOL-EXTRACTED SERUM [J].

DAUGHADAY, WH ;

MARIZ, IK ;

BLETHEN, SL .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1980, 51 (04) :781-788

← 1 2 3 4 →